Maud Toulmonde
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Maud Toulmonde has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
A. Italiano
Institut Bergonié, Bordeaux, France
9 shared publicationsN. Isambert
5 shared publications- Jean-Yves Blay
Medical Oncology Department Centre Léon Bérard Lyon France
4 shared publications - Nicolas Penel
Department of Medical Oncology Centre Oscar Lambret Lille France
4 shared publications A. Le Cesne
3 shared publications- Florence Duffaud
Hopital La Timone, Marseille, France; Institut Gustave Roussy, Villejuif, France; Centre Léon Bérard, Lyon, France; Hopital Edouard Herriot, Lyon, France; Novartis Pharma, Rueil, France
3 shared publications
Latest Publications
- 1 October 2017
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 99 (2) , S77
High dose (54 Gy) Pre-operative Tomotherapy for Retroperitoneal Liposarcoma: Results of a Phase 2 Multicenter Study
- 1 October 2017
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 99 (2) , S77
High dose (54 Gy) Pre-operative Tomotherapy for Retroperitoneal Liposarcoma: Results of a Phase 2 Multicenter Study
- 1 December 2016
- Published by Elsevier in European Journal of Cancer
- Vol. 69, S6
CHK1 targeting as a therapeutic strategy in soft-tissue sarcomas
- 1 December 2016
- Published by Elsevier in European Journal of Cancer
- Vol. 69, S6
CHK1 targeting as a therapeutic strategy in soft-tissue sarcomas
- 1 September 2015
- Published by Elsevier in European Journal of Cancer
- Vol. 51, S62-S63
324 Dose-seeking phase I trials (DSPT) of approved molecularly targeted therapies (MTT): Exhaustiveness and readability of published clinical reports
- 1 September 2015
- Published by Elsevier in European Journal of Cancer
- Vol. 51, S62-S63
324 Dose-seeking phase I trials (DSPT) of approved molecularly targeted therapies (MTT): Exhaustiveness and readability of published clinical reports
- 1 September 2015
- Published by Elsevier in European Journal of Cancer
- Vol. 51, S688
3400 Management of Desmoid Tumours (DT): A nationwide survey after labeling of 2 expert networks (RRePS and NetSarc)
- 1 September 2015
- Published by Elsevier in European Journal of Cancer
- Vol. 51, S688
3400 Management of Desmoid Tumours (DT): A nationwide survey after labeling of 2 expert networks (RRePS and NetSarc)
- Open Access
- 3 February 2014
- Published by Elsevier in Annals of Oncology
- Vol. 25 (3) , 730-734
Retroperitoneal sarcomas: patterns of care in advanced stages, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group
Retroperitoneal sarcomas (RPS) are heterogeneous. Advanced stages include unresectable locoregional (LR) disease, abdominal sarcomatosis and distant metastasis. There is no available report assessing palliative chemotherapy in advanced RPS. This study analyzes management and outcome in a large cohort of patients with advanced RPS, considering main histological subtypes separately. We conducted a retrospective analysis of adult patients diagnosed with a RPS between 1 January 1988 and 31 December 2008 across 12 centers of the French Sarcoma Group. All cases were centrally reviewed by an expert pathologist. Five-hundred eighty-six patients were included, 299 patients received palliative chemotherapy, with a median of two lines (range 0–8). Fifty patients underwent palliative surgery. Two hundred fifty-five patients (85%) were assessable for response after first line of chemotherapy. Among them, 69 patients (27%) had progressive disease, 145 (57%) had stable disease, 37 (14.5%) had partial response and 4 (1.5%) complete response. Median time from first line of palliative chemotherapy to progression was 5.9 months [4.9–7.3] and median overall survival (OS), 15.8 months [13–18]. In multivariate analysis, prognosis factors independently associated with poor OS were male gender, performance status (PS) >1 and grade >1. There was no difference according to stage of disease. Palliative surgery did not appear to add any survival benefit. These results emphasize the scarcity of available options for RPS in the advanced setting and the urgent need to develop new strategies. Patients with good PS should be included in clinical trials and best supportive care should be considered in those with poor PS.
- 3 February 2014
- Published by Elsevier in Annals of Oncology
- Vol. 25 (3) , 730-734
Open AccessRetroperitoneal sarcomas: patterns of care in advanced stages, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group
Retroperitoneal sarcomas (RPS) are heterogeneous. Advanced stages include unresectable locoregional (LR) disease, abdominal sarcomatosis and distant metastasis. There is no available report assessing palliative chemotherapy in advanced RPS. This study analyzes management and outcome in a large cohort of patients with advanced RPS, considering main histological subtypes separately. We conducted a retrospective analysis of adult patients diagnosed with a RPS between 1 January 1988 and 31 December 2008 across 12 centers of the French Sarcoma Group. All cases were centrally reviewed by an expert pathologist. Five-hundred eighty-six patients were included, 299 patients received palliative chemotherapy, with a median of two lines (range 0–8). Fifty patients underwent palliative surgery. Two hundred fifty-five patients (85%) were assessable for response after first line of chemotherapy. Among them, 69 patients (27%) had progressive disease, 145 (57%) had stable disease, 37 (14.5%) had partial response and 4 (1.5%) complete response. Median time from first line of palliative chemotherapy to progression was 5.9 months [4.9–7.3] and median overall survival (OS), 15.8 months [13–18]. In multivariate analysis, prognosis factors independently associated with poor OS were male gender, performance status (PS) >1 and grade >1. There was no difference according to stage of disease. Palliative surgery did not appear to add any survival benefit. These results emphasize the scarcity of available options for RPS in the advanced setting and the urgent need to develop new strategies. Patients with good PS should be included in clinical trials and best supportive care should be considered in those with poor PS.
- 25 April 2012
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 134 (1) , 325-332
Docetaxel rechallenge after a first response in non-resistant metastatic breast cancer: significant activity with manageable toxicity
Docetaxel is a major drug in metastatic breast cancer (MBC) treatment. At progression, rechallenge with docetaxel can be discussed, according to previous efficacy and tolerance, as long as it was stopped for reasons other than progression. Currently, no data are available outlining outcomes after this pragmatic approach in MBC. We retrospectively identified 72 patients with the following criteria: (i) objective response or stable disease with a previous line of treatment with docetaxel in the metastatic setting, (ii) discontinuation for a reason other than progression, (iii) rechallenge with docetaxel after a minimal docetaxel-free interval of 3 months. The main objectives were to evaluate overall response (ORR), time to progression (TTP), overall survival (OS) and toxicity at reintroduction of docetaxel. Median patient age was 57 years (range: 34–84). Docetaxel was reintroduced as a 2nd, 3rd, or ≥4th line of chemotherapy in the metastatic setting in 21, 46 and 33 % of cases, respectively. Previous agents used included capecitabine, anthracycline, and vinorelbine in 54, 40 and 21 % of cases, respectively. The median number of docetaxel cycles was 6 (range: 1–18). Among the 33 patients with disease assessed according to RECIST criteria, 14 (42.5 %) had a partial response and 11 (33.5 %) a stable disease >6 weeks. Among the 46 patients with an initial CA 15-3 increase, 34 (74 %) had a ≥50 % decrease of the value. Globally, 55 patients (76 %) obtained a benefit from the treatment. The median TTP and OS were 5.7 months (95 % CI: 5.0–6.3) and 10.2 months (95 % CI: 8.6–11.8), respectively. Forty-six patients (64 %) reported grade 1/2 toxicity, 23 patients (32 %) experienced grade 3/4 toxicity, mostly neutropenia (17 %) and fluid retention (10 %). There was no difference in median TTP after subsequent docetaxel in subgroup analyses. This retrospective analysis supports the pragmatic strategy to retreat patients with MBC with docetaxel when this drug has shown previous activity and was stopped for other causes than progression.
- 25 April 2012
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 134 (1) , 325-332
Docetaxel rechallenge after a first response in non-resistant metastatic breast cancer: significant activity with manageable toxicity
Docetaxel is a major drug in metastatic breast cancer (MBC) treatment. At progression, rechallenge with docetaxel can be discussed, according to previous efficacy and tolerance, as long as it was stopped for reasons other than progression. Currently, no data are available outlining outcomes after this pragmatic approach in MBC. We retrospectively identified 72 patients with the following criteria: (i) objective response or stable disease with a previous line of treatment with docetaxel in the metastatic setting, (ii) discontinuation for a reason other than progression, (iii) rechallenge with docetaxel after a minimal docetaxel-free interval of 3 months. The main objectives were to evaluate overall response (ORR), time to progression (TTP), overall survival (OS) and toxicity at reintroduction of docetaxel. Median patient age was 57 years (range: 34–84). Docetaxel was reintroduced as a 2nd, 3rd, or ≥4th line of chemotherapy in the metastatic setting in 21, 46 and 33 % of cases, respectively. Previous agents used included capecitabine, anthracycline, and vinorelbine in 54, 40 and 21 % of cases, respectively. The median number of docetaxel cycles was 6 (range: 1–18). Among the 33 patients with disease assessed according to RECIST criteria, 14 (42.5 %) had a partial response and 11 (33.5 %) a stable disease >6 weeks. Among the 46 patients with an initial CA 15-3 increase, 34 (74 %) had a ≥50 % decrease of the value. Globally, 55 patients (76 %) obtained a benefit from the treatment. The median TTP and OS were 5.7 months (95 % CI: 5.0–6.3) and 10.2 months (95 % CI: 8.6–11.8), respectively. Forty-six patients (64 %) reported grade 1/2 toxicity, 23 patients (32 %) experienced grade 3/4 toxicity, mostly neutropenia (17 %) and fluid retention (10 %). There was no difference in median TTP after subsequent docetaxel in subgroup analyses. This retrospective analysis supports the pragmatic strategy to retreat patients with MBC with docetaxel when this drug has shown previous activity and was stopped for other causes than progression.
- 30 September 2011
- Published by Elsevier in European Journal of Cancer
- Vol. 47, S349
5062 POSTER Rechallenge With Docetaxel After a First Response In Metastatlc Breast Cancer – a Significant Activity With Manageable Toxicity
- 30 September 2011
- Published by Elsevier in European Journal of Cancer
- Vol. 47, S349
5062 POSTER Rechallenge With Docetaxel After a First Response In Metastatlc Breast Cancer – a Significant Activity With Manageable Toxicity
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15) , 10071
Advanced well-differentiated/dedifferentiated liposarcomas: Role of chemotherapy and survival.
10071 Background: Data regarding the role of systemic therapy in patients (pts) with advanced well-differentiated/dedifferentiated liposarcomas (WLPS/DDLPS) are limited. Methods: From 2000 to 2010, 166 pts with a confirmed diagnosis of WDLPS/DDLPS were referred to one of the 8 participating institutions, and their medical records reviewed. Results: Median age was 63 years (range 34-84). Thirty pts had WDLPS and 136 pts had DDLPS. Primary tumor sites were: retroperitoneum n=120 (73%), limb n=19 (11%), other n=27 (16%). 111 pts (67%) had metastatic disease (peritoneal sarcomatosis n=75; lung n=30, liver n=19, bone n=5) and 55 pts (33%) had locoregional unresectable disease. 27 pts (16%) had ≥ 2 metastatic sites. 103 pts (62%) received 1st line single agent chemotherapy. 131 pts (79%) received a 1st line anthracycline-containing regimen (doxorubicin n=64, doxorubicin + ifosfamide and/or dacarbazine: n=45, other: n=22). Non-anthracycline regimens were: metronomic cyclophosphamide or etoposide: n=17; trabectedin: n=4, others: n=14. RECIST objective response was observed in 18 pts (11%), all treated with anthracyclines. Response rate was higher in pts receiving combination chemotherapy: 17% vs 7%, p=0.03. 62 pts (37%) had stable disease > 6 months. Median progression-free survival (PFS) was 5.2 months (95% CI: 3.4-7.0). On multivariate analysis, performance status (PS) ≥ 2 was the sole factor significantly associated with poor PFS (Hazard ratio [HR]= 2.2; 95% CI 1.4–3.5; p3 (HR= 2.2; 95% CI 1.2–3.9; p = 0.01) were the sole factors significantly associated with poor OS. Conclusions: Chemotherapy is associated with a non-progression rate of about 50% in pts with advanced WDLPS/DDLPS. Combination chemotherapy gives higher response rate than single agent but appears to have no impact on PFS or OS. OS of pts with advanced WDLPS/DDLPS is poor, even if visceral metastatic disease is less frequent than in other sarcomas. Best supportive care should be considered in pts with poor PS.
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15) , 10071
Advanced well-differentiated/dedifferentiated liposarcomas: Role of chemotherapy and survival.
10071 Background: Data regarding the role of systemic therapy in patients (pts) with advanced well-differentiated/dedifferentiated liposarcomas (WLPS/DDLPS) are limited. Methods: From 2000 to 2010, 166 pts with a confirmed diagnosis of WDLPS/DDLPS were referred to one of the 8 participating institutions, and their medical records reviewed. Results: Median age was 63 years (range 34-84). Thirty pts had WDLPS and 136 pts had DDLPS. Primary tumor sites were: retroperitoneum n=120 (73%), limb n=19 (11%), other n=27 (16%). 111 pts (67%) had metastatic disease (peritoneal sarcomatosis n=75; lung n=30, liver n=19, bone n=5) and 55 pts (33%) had locoregional unresectable disease. 27 pts (16%) had ≥ 2 metastatic sites. 103 pts (62%) received 1st line single agent chemotherapy. 131 pts (79%) received a 1st line anthracycline-containing regimen (doxorubicin n=64, doxorubicin + ifosfamide and/or dacarbazine: n=45, other: n=22). Non-anthracycline regimens were: metronomic cyclophosphamide or etoposide: n=17; trabectedin: n=4, others: n=14. RECIST objective response was observed in 18 pts (11%), all treated with anthracyclines. Response rate was higher in pts receiving combination chemotherapy: 17% vs 7%, p=0.03. 62 pts (37%) had stable disease > 6 months. Median progression-free survival (PFS) was 5.2 months (95% CI: 3.4-7.0). On multivariate analysis, performance status (PS) ≥ 2 was the sole factor significantly associated with poor PFS (Hazard ratio [HR]= 2.2; 95% CI 1.4–3.5; p3 (HR= 2.2; 95% CI 1.2–3.9; p = 0.01) were the sole factors significantly associated with poor OS. Conclusions: Chemotherapy is associated with a non-progression rate of about 50% in pts with advanced WDLPS/DDLPS. Combination chemotherapy gives higher response rate than single agent but appears to have no impact on PFS or OS. OS of pts with advanced WDLPS/DDLPS is poor, even if visceral metastatic disease is less frequent than in other sarcomas. Best supportive care should be considered in pts with poor PS.
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15) , 10044
Patterns of care, prognosis, and survival of patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib.
10044 Background: Data regarding the management and outcome of metastatic GIST patients (pts) refractory to 1st line imatinib (I) and 2nd sunitinib (S) are limited. Methods: Eleven institutions participated in this retrospective study. A preliminary analysis based on the data from 176 pts treated in 9 institutions is presented in this Final analysis will be presented at the meeting. Results: Median age was 57 years (range 18-84). Median progression free-survival (PFS) on 1st line I and 2nd line S were 22.4 months (mo) (95% CI: 19.2-26.2) and 8.2 mo (95% CI: 6-10.4), respectively. Pts who were treated with 3rd or 4th line sorafenib (vs other treatment) had significantly higher PFS, although improvement in overall survival (OS) was observed in 4th line only. On univariate analysis, age, performance status ≥2, haemoglobin <10g/dl, albumin < 35g/l and primary mutation on exon 11 or 9 (versus wild-type or PDGFRα mutation) were significantly associated with inferior OS. On multivariate analysis, albumin level (HR=2.2, 95% CI 1.1–4.4; p = 0.03) and mutational status (HR=4.1, 95% CI 1.4–11.9; p = 0.01) were the sole independent predictors of poor OS. Conclusions: This collaborative study is the largest one focusing on the management and survival of GIST patients refractory to I and S. Pts more likely to carry secondary mutations seem to have the worst outcome. Rechallenge with I is associated with limited clinical benefit, but appears superior to best supportive care. Sorafenib may provide the best treatment option in case of clinical trial ineligibility, given these data. Treatment N PFS OS Median (months) 95% CI P value Median (months) 95% CI P value 3rd-line setting 157 3.6 [3.0-4.2] - 9.5 [7.7-11.4] - Imatinib (I) 23 3.6 p = 0.001 9.9 p < 0.0001 I + other agent (not “ib”) 26 2.7 8.6 Nilotinib (N) 26 3.9 13.6 Sorafenib 54 6.1 11.3 Other 10 2.5 9.1 Best supportive care (BSC) 18 2.1 2.3 4th line setting 104 2.5 [1.9-3.0] - 5.1 [3.6-6.7] - I 18 4.9 p = 0.008 7.4 p < 0.0001 I + other agent (not “ib”) 13 1.9 5.5 N 14 3.8 5.4 Sorafenib 14 7.5 11.5 Other 20 1.8 8.2 BSC 25 1.6 1.6 5th line setting 45 2.6 [1.7-3.6] - 4.4 [2.7-6.0] - 6th line setting 18 1.4 [0.6-2.2] - 2.8 [1.4-4.2] -
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15) , 10044
Patterns of care, prognosis, and survival of patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib.
10044 Background: Data regarding the management and outcome of metastatic GIST patients (pts) refractory to 1st line imatinib (I) and 2nd sunitinib (S) are limited. Methods: Eleven institutions participated in this retrospective study. A preliminary analysis based on the data from 176 pts treated in 9 institutions is presented in this Final analysis will be presented at the meeting. Results: Median age was 57 years (range 18-84). Median progression free-survival (PFS) on 1st line I and 2nd line S were 22.4 months (mo) (95% CI: 19.2-26.2) and 8.2 mo (95% CI: 6-10.4), respectively. Pts who were treated with 3rd or 4th line sorafenib (vs other treatment) had significantly higher PFS, although improvement in overall survival (OS) was observed in 4th line only. On univariate analysis, age, performance status ≥2, haemoglobin <10g/dl, albumin < 35g/l and primary mutation on exon 11 or 9 (versus wild-type or PDGFRα mutation) were significantly associated with inferior OS. On multivariate analysis, albumin level (HR=2.2, 95% CI 1.1–4.4; p = 0.03) and mutational status (HR=4.1, 95% CI 1.4–11.9; p = 0.01) were the sole independent predictors of poor OS. Conclusions: This collaborative study is the largest one focusing on the management and survival of GIST patients refractory to I and S. Pts more likely to carry secondary mutations seem to have the worst outcome. Rechallenge with I is associated with limited clinical benefit, but appears superior to best supportive care. Sorafenib may provide the best treatment option in case of clinical trial ineligibility, given these data. Treatment N PFS OS Median (months) 95% CI P value Median (months) 95% CI P value 3rd-line setting 157 3.6 [3.0-4.2] - 9.5 [7.7-11.4] - Imatinib (I) 23 3.6 p = 0.001 9.9 p < 0.0001 I + other agent (not “ib”) 26 2.7 8.6 Nilotinib (N) 26 3.9 13.6 Sorafenib 54 6.1 11.3 Other 10 2.5 9.1 Best supportive care (BSC) 18 2.1 2.3 4th line setting 104 2.5 [1.9-3.0] - 5.1 [3.6-6.7] - I 18 4.9 p = 0.008 7.4 p < 0.0001 I + other agent (not “ib”) 13 1.9 5.5 N 14 3.8 5.4 Sorafenib 14 7.5 11.5 Other 20 1.8 8.2 BSC 25 1.6 1.6 5th line setting 45 2.6 [1.7-3.6] - 4.4 [2.7-6.0] - 6th line setting 18 1.4 [0.6-2.2] - 2.8 [1.4-4.2] -